First-round funding for eye technology firm HyperBranch
This article was originally published in Clinica
Executive Summary
HyperBranch Medical Technology, a Raleigh, North Carolina-based developer of eye surgery products, has raised $6m in a first round of venture capital financing. The funds, contributed by The Aurora Funds (Durham, North Carolina) and HIG Ventures (Miami, Florida), will help the company carry out preclinical and clinical development of its two lead products, a synthetic lens for use in cataract surgery and wound-sealing glue for use in ophthalmics.